Dawson James analyst James McIlree downgrades Crown ElectroKinetics (NASDAQ:CRKN) from Buy to Neutral.
X4 Pharma Highlights ‘Significant Reduction’ Rate In Severity, Duration Of Infections
X4 Pharmaceuticals Inc (NASDAQ: XFOR) highlighted new data from a Phase 3 clinical trial of once-daily, oral mavorixafor in